Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 4, 2012, Pages 617-626

  Patriarca, Francesca ^a   Einsele, Hermann ^b   Spina, Francesco ^c   Bruno, Benedetto ^d   Isola, Miriam ^e   Nozzoli, Chiara ^f   Nozza, Andrea ^g   Sperotto, Alessandra ^a   Morabito, Fortunato ^h   Stuhler, Gernot ^b   Festuccia, Moreno ^d   Bosi, Alberto ^f   Fanin, Renato ^a   Corradini, Paolo ⁱ  

^a Department of Experimental Clinical Medicine   (Italy)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e Department of Experimental Clinical Medicine   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h Unit of Geriatrics   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

Donor versus no donor analysis; Novel drugs; Reduced intensity regimens

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOGRAFT; CHEMOSENSITIVITY; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DONOR; HLA TYPING; HUMAN; INTENTION TO TREAT ANALYSIS; KARYOTYPE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RELAPSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIBLING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; THALIDOMIDE; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84858075401     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.026     Document Type: Article

References (45)

1. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Eng J Med 1999, 341:1565-1571.
2. Richardson P.G., Sonneveld P., Schuster M.W., et al. for the Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose desametasone for relapsed multiple myeloma. N Eng J Med 2005, 352:2487-2498.
3. Weber D.M., Chen C., Niesvizky R., for the Multiple Myeloma (009) Study Investigators, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
4. Dimopoulos M., Spencer A., Attal M., for the Multiple Myeloma (010) Study Investigators, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
5. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
6. Martinelli G., Terragna C., Zamagni E., et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic cells for multiple myeloma. J Clin Oncol 2000, 18:2273-2281.
7. Corradini P., Cavo M., Lokhorst H., et al. for the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003, 102:1927-1929.
8. Björkstrand B.B., Ljungman P., Svensson H., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996, 88:4711-4718.
9. Gahrton G., Svensson H., Cavo M., for the European Group for Blood and Marrow Transplantation, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001, 113:209-216.
10. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003, 102:3447-3454.
11. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
12. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110-1120.
13. Gahrton G., Björkstrand B., Iacobelli S., on behalf of the Chronic Leukemia Working Party, et al. Long-term follow-up of upfront tandem autologous-RIC (reduced intensity conditioning) allogeneic transplantation versus autologous transplantation (NMAM2000) in multiple myeloma [abstract]. Bone Marrow Transplant 2010, 45:85a.
14. Rosiñol L., Pérez-Simón J.A., Sureda A., et al. for the Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM). A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
15. Crawley C., Lalancette M., Szydlo R., et al. for the Chronic Leukaemia Working Party of the EBMT. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factor from the Chronic Leukemia Working Party of EBMT. Blood 2005, 105:4532-4539.
16. Badros A., Barlogie B., Siegel E., et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002, 20:1295-1303.
17. Lee C.K., Badros A., Barlogie B., et al. Prognostic factor in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003, 31:73-80.
18. Peggs K.S., Mackinnon S., Williams C.D., et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003, 9:257-265.
19. Bruno B., Sorasio R., Patriarca F., for the Gruppo Italiano Trapianto Midollo Osseo, et al. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. Eur J Haematol 2007, 78:330-337.
20. Pérez-Simón J.A., Martino R., Alegre A., et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative transplantation. Br J Haematol 2003, 121:104-108.
21. Einsele H., Schäfer H.J., Hebart H., et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003, 121:411-418.
22. Georges G.E., Maris M.B., Maloney D.G., et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007, 13:423-432.
23. Kröger N., Sayer H.G., Schwerdtfeger R., et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002, 100:3919-3924.
24. Kröger N., Shimoni A., Schilling G., et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol 2010, 148:323-331.
25. Osman K., Elliott B., Mandeli J., et al. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma. Am J Hematol 2010, 85:249-254.
26. Efebera Y.A., Qureshi S.R., Cole S.M., et al. Reduced-intensity hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant 2010, 16:1122-1129.
27. Kröger N., Badbaran A., Lioznov M., et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009, 37:791-798.
28. Durie B.G., Harousseau J.L., Miguel J.S., et al. for the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
29. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
30. Sullivan K.M., Agura E., Anasetti C., et al. Chronic graft-versus-host disease and other complications of bone marrow transplantation. Semin Hematol 1991, 28:250-259.
31. Harousseau J.L., Attal M., Leleu X., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006, 91:1498-1505.
32. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide-dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet 2010, 376:2075-2085.
33. de Lavallade H., El-Cheikh J., Faucher C., et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008, 41:953-960.
34. Attal M., Harousseau J.L., Stoppa A.M., for the Intergroupe Français du Myélome, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996, 335:91-97.
35. Child J.A., Morgan G.J., Davies F.E., for the Medical Research Council Adult Leukaemia Working Party, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
36. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Clinical implication of (11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005, 106:2837-2840.
37. Barlogie B., Pineda-Roman M., van Rhee F., et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008, 112:3115-3121.
38. Jagannath S., Richardson P.G., Sonneveld P., et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007, 21:151-157.
39. Zonder J.A., Crowley J.J., Bolejack V., et al. A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly diagnosed multiple myeloma (NDMM): impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results [abstract]. J Clin Oncol 2008, 26. abstract 8521.
40. Kapoor P., Kumar S., Fonseca R., et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009, 114:518-521.
41. Biagi J.J., Mileskin L., Grigg A.P., et al. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001, 28:1145-1150.
42. Patriarca F., Zaja F., Silvestri F., et al. Efficacy of bortezomib therapy for extramedullary repase of myeloma after autologous and non-myeloablative allogeneic transplantation. Bone Marrow Transplant 2005, 90:278-279.
43. Zeiser R., Descler B., Bertz H., et al. Extramedulalry vs medullary repase after autologous or allogeneic hematopoietic stem cell transplantation in multiple myeloma and its correlation to clinical outcome. Bone Marrow Transplant 2004, 34:1057-1065.
44. Sarina B., Castagna L., Farina L., et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010, 115:3671-3677.
45. Lokhorst H., Einsele H., Vesole D., et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem cell transplantation for multiple myeloma. J Clin Oncol 2010, 28:4521-4530.